An open-label study to evaluate contraceptive efficacy and safety of the transdermal contraceptive system of norelgestromin and ethinyl estradiol
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs Ethinylestradiol/norelgestromin (Primary)
- Indications Pregnancy
- Focus Therapeutic Use
- Sponsors Janssen-Cilag
- 23 Oct 2007 The expected completion date for this trial is now 1 Dec 2004.
- 22 Oct 2007 Status changed from in progress to completed.
- 25 Oct 2006 New trial record.